SVCP
CRSP icon

Silicon Valley Capital Partners’s CRISPR Therapeutics CRSP Stock Holding History

Silicon Valley Capital Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100
Closed -$6.48K – 269
2025
Q3 		$6.48K Buy
+100
New +$5.74K ﹤0.01% 238

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GP
GSK plc London $599M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Silicon Valley Capital Partners's CRSP Position: Q4 2025 in Review

Silicon Valley Capital Partners sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 100 shares — an estimated $6.48K sold.

Silicon Valley Capital Partners first reported a position in CRSP in Q3 2025 and held it in 1 quarter. The position peaked at $6.48K in Q3 2025. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

  • Silicon Valley Capital Partners reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Silicon Valley Capital Partners sold 100 CRISPR Therapeutics shares in Q4 2025, an estimated $6.48K.
  • Silicon Valley Capital Partners first reported a position in CRISPR Therapeutics in Q3 2025 and held it in 1 quarter.
  • Silicon Valley Capital Partners's CRISPR Therapeutics position peaked at $6.48K in Q3 2025.
  • 479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Silicon Valley Capital Partners's 13F filing for Q4 2025, filed 13 Feb 2026.